France debates the sale of its top painkiller, Doliprane, to US investors, raising national sovereignty concerns.

France is debating the proposed sale of Doliprane, its top-selling painkiller, to US investors, sparking concerns over national sovereignty. Sanofi is negotiating with private equity firm Clayton, Dubilier & Rice to sell a 50% stake in its subsidiary Opella. French officials demand that Opella's headquarters and decision-making remain in France, emphasizing job security and production guarantees. Without compliance, the government may block the deal or seek state involvement.

October 14, 2024
13 Articles